Form 8-K IDEAYA Biosciences, Inc. For: Apr 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ideaya Biosciences (IDYA) PT Raised to $52 at Mizuho, 'we recommend being opportunistic'
April 13, 2026 3:08 PM EDTMizuho analyst Graig Suvannavejh raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $52.00 (from $46.00) while maintaining a Outperform rating.
The analyst comments "Following up on Quick Take comments earlier today (LINK) on positive P2/3 data for darovasertib/daro (a protein kinase C/PKC... More
Ideaya Biosciences (IDYA) PT Raised to $65 at Truist Securities
April 13, 2026 2:05 PM EDTTruist Securities analyst Greg Renza raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $65.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Today's disclosure highlights daro's best-in-class PFS and consistent efficacy to an earlier study which together with a favorable OS trend... More
